scholarly journals Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia

2019 ◽  
Vol 3 (17) ◽  
pp. 2598-2603 ◽  
Author(s):  
Brian M. Barth ◽  
Weiyuan Wang ◽  
Paul T. Toran ◽  
Todd E. Fox ◽  
Charyguly Annageldiyev ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Therapeutic Efficacy ◽  
Myeloid Leukemia ◽  
Sphingolipid Metabolism ◽  
Key Points ◽  
C6 Ceramide ◽  
Acute Myeloid

Key Points Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.

scholarly journals CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

Blood ◽  
2013 ◽  
Vol 122 (7) ◽  
pp. 1316-1324 ◽  
Author(s):  
Margaret L. Green ◽  
Wendy M. Leisenring ◽  
Hu Xie ◽  
Roland B. Walter ◽  
Marco Mielcarek ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Early Relapse ◽  
Relapse Risk ◽  
Allogeneic Hct ◽  
Increased Risk ◽  
Key Points ◽  
Cmv Reactivation ◽  
Reduced Risk ◽  
Acute Myeloid

Key Points CMV reactivation after HCT is associated with a reduced risk of early relapse in patients with AML but not other disease groups. The benefit, however, is offset by an increased risk of nonrelapse mortality.

scholarly journals Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target

Blood ◽  
2015 ◽  
Vol 125 (15) ◽  
pp. 2386-2396 ◽  
Author(s):  
Francis Mussai ◽  
Sharon Egan ◽  
Joseph Higginbotham-Jones ◽  
Tracey Perry ◽  
Andrew Beggs ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Therapeutic Target ◽  
Myeloid Leukemia ◽  
Leukemia Blast ◽  
Key Points ◽  
Acute Myeloid Leukemia Blast ◽  
Acute Myeloid ◽  
Novel Therapeutic

Key Points Arginase depletion with BCT-100 pegylated recombinant human arginase is cytotoxic to AML blasts.

scholarly journals Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia

Blood ◽  
2017 ◽  
Vol 129 (6) ◽  
pp. 771-782 ◽  
Author(s):  
Jason A. Powell ◽  
Alexander C. Lewis ◽  
Wenying Zhu ◽  
John Toubia ◽  
Melissa R. Pitman ◽  
...  
Keyword(s):  
Cell Death ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Sphingosine Kinase ◽  
Sphingosine Kinase 1 ◽  
Key Points ◽  
Dependent Cell ◽  
Acute Myeloid

Key Points Inhibition of SPHK1 in human AML cells induces MCL1 degradation and caspase-dependent cell death. SPHK1 inhibitors reduce leukemic burden and prolong survival in orthotopic patient-derived xenografts of AML.

scholarly journals Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia

Blood ◽  
2016 ◽  
Vol 128 (14) ◽  
pp. 1854-1861 ◽  
Author(s):  
Eduard J. Libourel ◽  
Clara P. W. Klerk ◽  
Yvette van Norden ◽  
Moniek P. M. de Maat ◽  
Marieke J. Kruip ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Disseminated Intravascular Coagulation ◽  
Arterial Thrombosis ◽  
Myeloid Leukemia ◽  
Strong Predictor ◽  
Newly Diagnosed ◽  
Intravascular Coagulation ◽  
Key Points ◽  
D Dimer ◽  
Acute Myeloid

Key Points A high D-dimer level strongly predicts symptomatic venous and arterial thrombosis in newly diagnosed AML. Thrombosis occurs in up to 10% of patients with newly diagnosed AML.

scholarly journals Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia

Blood ◽  
2016 ◽  
Vol 127 (11) ◽  
pp. 1449-1458 ◽  
Author(s):  
Weiwei Shen ◽  
Mrinal M. Patnaik ◽  
Autumn Ruiz ◽  
Stephen J. Russell ◽  
Kah-Whye Peng
Keyword(s):  
Acute Myeloid Leukemia ◽  
Vesicular Stomatitis Virus ◽  
Myeloid Leukemia ◽  
Therapeutic Outcome ◽  
Key Points ◽  
Vesicular Stomatitis ◽  
Immunocompetent Mice ◽  
Acute Myeloid

Key Points IV therapy with oncolytic VSV-IFNβ-NIS virus extends survival of immunocompetent mice with AML. The therapeutic outcome of VSV-IFNβ-NIS–treated mice with AML is augmented by anti-PD-L1 immunotherapy.

scholarly journals CDX2 regulates ACE expression in blood development and leukemia cells

2021 ◽  
Vol 5 (7) ◽  
pp. 2012-2016
Author(s):  
Reine El Omar ◽  
Emmanuelle Julien ◽  
Katia Biasch ◽  
Blandine Guffroy ◽  
Bruno Lioure ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Homeobox Gene ◽  
Mouse Embryos ◽  
Leukemia Cells ◽  
Converting Enzyme ◽  
Key Points ◽  
Human Acute Myeloid Leukemia ◽  
Human And Mouse ◽  
Acute Myeloid

Key Points Expression of caudal-related homeobox gene 2 (CDX2) and angiotensin-converting enzyme (ACE) correlates during hematopoietic emergence. This emergence occurs in human and mouse embryos and in human acute myeloid leukemia; CDX2 homeoprotein also binds to the ACE promoter.

scholarly journals MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells

Blood ◽  
2014 ◽  
Vol 123 (5) ◽  
pp. 734-742 ◽  
Author(s):  
Suiyang Liu ◽  
Li Yin ◽  
Dina Stroopinsky ◽  
Hasan Rajabi ◽  
Alexandre Puissant ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Receptor Activation ◽  
Leukemia Cells ◽  
Receptor Targeting ◽  
Potential Approach ◽  
Key Points ◽  
Flt3 Inhibitors ◽  
Acute Myeloid Leukemia Cells ◽  
Acute Myeloid

Key Points The MUC1-C oncoprotein is aberrantly expressed in AML cells and contributes to activation of the mutant FLT3 receptor. Targeting MUC1-C thus inhibits FLT3 signaling and represents a potential approach for AML cells resistant to FLT3 inhibitors.

Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia

2015 ◽  
Vol 11 (4) ◽  
pp. 691-701 ◽  
Author(s):  
A. Estella-Hermoso de Mendoza ◽  
R. Castello-Cros ◽  
E. Imbuluzqueta ◽  
C. Cirauqui ◽  
R. Pippa ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Therapeutic Efficacy ◽  
Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity

2018 ◽  
Vol 2 (16) ◽  
pp. 2095-2103 ◽  
Author(s):  
Mary Eapen ◽  
Ruta Brazauskas ◽  
Michael Hemmer ◽  
Waleska S. Perez ◽  
Patricia Steinert ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Clinical Remission ◽  
Myeloid Leukemia ◽  
Conditioning Regimen ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
Key Points ◽  
Acute Myeloid

Key Points Bu4/Cy, Flu/Bu4, and Flu/Mel are optimal regimens for patients with AML in clinical remission or those with MDS. Flu/Mel, considered a less-intense regimen, is ideal for less fit patients.

Sign in / Sign up

Export Citation Format

Share Document